Date: October 6, 2026
Regulatory Compliance Disclosure
Shukra Pharmaceuticals Ltd. has submitted a formal response to the National Stock Exchange of India Limited (NSE) regarding a surveillance query. The query, received via email dated October 6, 2026, concerned a significant increase in the company's security price across exchanges in the recent past.
The company's Compliance Officer, Shivkant Dhakad, stated that the firm strictly adheres to the compliance requirements under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company asserts that all material events and corporate actions are disclosed to the stock exchanges promptly as and when they arise.
Clarification on Price Movement
The company explicitly clarified that there is no unannounced material information or pending price-sensitive announcement that could influence the trading volume or price behavior of the company's shares. The recent spurt in the share price is attributed entirely to market-driven conditions and natural trading dynamics. The company stated it has no role or influence over this movement.